Chaturvedi Shailesh, McLaren Catherine, Schofield Andrew C, Ogston Keith N, Sarkar Tarun K, Hutcheon Andrew W, Miller Iain D, Heys Steven D
Department of Surgery, Medical School, University of Aberdeen, UK.
Breast Cancer Res Treat. 2005 Sep;93(2):151-8. doi: 10.1007/s10549-005-4615-y.
This study aimed to evaluate patterns of local and distant disease recurrence in patients having primary chemotherapy and compared patterns of relapse in patients with a complete pathological response with those who had residual breast disease. This is an observational study using a sequential series of patients treated with primary chemotherapy. They were followed up for a minimum of 5 years. All data was collected prospectively. Three hundred forty-one consecutive patients with breast cancer were treated with up to eight cycles of doxorubicin-based chemotherapy. Clinical and pathological response rates were evaluated and patients were followed up for disease recurrence (local and distant) and overall survival. Fifty-two patients (16.5%) had a complete pathological response to chemotherapy. Distant disease recurrence occurred in nine patients (17.3%) but no local recurrence was observed. In patients not having a complete pathological response, 86 patients (32.6%) subsequently developed metastases. Local recurrence of disease occurred in 12 (4.5%). There was a statistically significant difference in overall survival between patients whose tumours had a complete pathological response compared with patients who had residual disease in the breast following chemotherapy (88% versus 70% at 5 years, p = 0.036). Following primary chemotherapy, about 84% of patients had residual disease in the breast. Surgery is necessary to ensure complete removal of residual tumour and excellent rates of local control are achievable. A complete pathological response is associated with fewer local and distant recurrences as well as improved survival although there are no differences in time to development of metastatic relapse.
本研究旨在评估接受原发性化疗患者的局部和远处疾病复发模式,并比较病理完全缓解患者与有残留乳腺疾病患者的复发模式。这是一项观察性研究,采用一系列接受原发性化疗的患者。对他们进行了至少5年的随访。所有数据均前瞻性收集。341例连续乳腺癌患者接受了多达8个周期的以阿霉素为基础的化疗。评估临床和病理缓解率,并对患者进行疾病复发(局部和远处)及总生存期的随访。52例患者(16.5%)化疗后病理完全缓解。9例患者(17.3%)出现远处疾病复发,但未观察到局部复发。在未达到病理完全缓解的患者中,86例(32.6%)随后发生转移。12例(4.5%)出现疾病局部复发。化疗后肿瘤病理完全缓解的患者与乳腺有残留疾病的患者相比,总生存期有统计学显著差异(5年时分别为88%和70%,p = 0.036)。原发性化疗后,约84%的患者乳腺有残留疾病。手术对于确保残留肿瘤的完全切除是必要的,并且可以实现良好的局部控制率。病理完全缓解与局部和远处复发较少以及生存期改善相关,尽管发生转移性复发的时间没有差异。